Hillelsohn Joel H, Liu Grace T, Hymowitz Maggie B, Shrivastava Anurag, Schultz Jeffrey S
Montefiore Medical Center, The Henkind Eye Institute , Bronx, New York.
J Ocul Pharmacol Ther. 2015 Apr;31(3):169-73. doi: 10.1089/jop.2014.0058. Epub 2015 Feb 6.
To determine if a pharmacological test could be developed to determine iris dilator dysfunction in patients taking tamsulosin.
Patients taking tamsulosin and controls were recruited from the Urology and Ophthalmology clinics at the Montefiore Medical Center. The patient's right eye (OD) was dilated with phenylephrine hydrochloride 2.5% and tropicamide 1%. The patient's left eye (OS) was dilated with tropicamide 1% alone. Forty minutes after dilation, pupillary diameter was measured in both eyes.
Thirty-eight tamsulosin subjects and 43 controls met the inclusion criteria for the study. The tamsulosin-treated patients dilated less with phenylephrine than controls (0.61±0.4 vs. 1.10±0.45 mm, respectively P<0.001). Receiver operating characteristic curves comparing maximal pupillary dilation versus differential pupillary dilation in tamsulosin patients relative to controls shows a greater area under the curve for differential dilation (0.8 vs. 0.6, respectively). A correlation between smooth muscle dysfunction and length of time on tamsulosin was observed. Patients using tamsulosin for <1 month had an average OD-OS difference of 0.85±0.5 mm. Patients who were on tamsulosin for >1 month had an average OD-OS difference of 0.52±0.32 mm (P<0.01, Mann-Whitney).
Patients treated with tamsulosin demonstrated a significantly decreased iris dilatory response to the selective adrenergic effects of phenylephrine compared to controls. Additionally, it appears that longer duration of exposure to tamsulosin increases the likelihood of dilator dysfunction.
确定是否可以开发一种药理学测试来确定服用坦索罗辛的患者的虹膜扩张肌功能障碍。
从蒙特菲奥里医疗中心的泌尿外科和眼科诊所招募服用坦索罗辛的患者和对照组。用2.5%的盐酸去氧肾上腺素和1%的托吡卡胺扩张患者的右眼(OD)。仅用1%的托吡卡胺扩张患者的左眼(OS)。散瞳40分钟后,测量双眼的瞳孔直径。
38名服用坦索罗辛的受试者和43名对照组符合该研究的纳入标准。与对照组相比,接受坦索罗辛治疗的患者对去氧肾上腺素的散瞳作用较小(分别为0.61±0.4与1.10±0.45毫米,P<0.001)。比较坦索罗辛患者与对照组最大瞳孔扩张与瞳孔差异扩张的受试者工作特征曲线显示,差异扩张的曲线下面积更大(分别为0.8与0.6)。观察到平滑肌功能障碍与服用坦索罗辛的时间长短之间存在相关性。服用坦索罗辛<1个月的患者OD-OS平均差异为0.85±0.5毫米。服用坦索罗辛>1个月的患者OD-OS平均差异为0.52±0.32毫米(P<0.01,曼-惠特尼检验)。
与对照组相比,接受坦索罗辛治疗的患者对去氧肾上腺素的选择性肾上腺素能作用的虹膜扩张反应明显降低。此外,似乎接触坦索罗辛的时间越长,扩张肌功能障碍的可能性就越大。